Home › Funds › Palo Alto Investors LP › TSHA

Palo Alto Investors LP position in TSHA

TAYSHA GENE THERAPIES INC · Health Care

Palo Alto Investors LP reported holding 1,337,217 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q3 2026 13F filing — a position valued at US$6.5M, representing 0.97% of its reported portfolio and ranking #25 among its reported holdings. Palo Alto Investors LP has disclosed TSHA holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)1.34M sh
Reported value held$6.51M
Portfolio Weight0.97%
First reportedQ4 2023
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Palo Alto Investors LP's TSHA position evolved

Palo Alto Investors LP first disclosed a stake in TSHA in Q4 2023 at 529,861 shares (US$938K). The position peaked in Q2 2026 at 1,391,382 shares, worth US$9.5M. Across 12 filings, Palo Alto Investors LP increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 1,337,217 shares valued at US$6.5M — a reduction of -54,165 shares quarter over quarter.. Notable position changes include a 53% increase in Q1 2024 (shares fell 22% over the following quarter), a 75% increase in Q1 2025 (shares rose 66% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 529.86K $937.85K New
Q1 2024 811.27K $2.33M Add
Q2 2024 811.27K $1.82M Hold
Q3 2024 811.27K $1.63M Hold
Q4 2024 811.27K $1.40M Hold
Q1 2025 1.42M $1.97M Add
Q2 2025 1.25M $2.88M Reduce
Q3 2025 1.25M $4.07M Hold
Q4 2025 1.18M $6.51M Reduce
Q1 2026 1.39M $6.22M Add
Q2 2026 1.39M $9.48M Hold
Q3 2026 1.34M $6.51M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TSHA and 13F data

TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 46 other funds we track also report a position in TSHA — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$148.2M), Avoro Capital Advisors LLC (US$116.3M), Vestal Point Capital, LP (US$87.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TSHA

All TSHA fund holders →

FAQ

How long has Palo Alto Investors LP held TSHA?

Palo Alto Investors LP has disclosed TSHA holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Palo Alto Investors LP's current position in TSHA?

As of Q3 2026, Palo Alto Investors LP holds 1.34M shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $6.51M, representing 0.97% of its reported portfolio and ranking #25.

Has Palo Alto Investors LP been buying or selling TSHA?

In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in TSHA. The position peaked in Q2 2026 at 1.39M shares.

Which other funds hold TSHA?

Other major institutional holders of TSHA include RA CAPITAL MANAGEMENT, L.P., Avoro Capital Advisors LLC, Vestal Point Capital, LP, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.